Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
136. |
ECCT/16/10/01 | INVICTUS INVESTIGATION OF RHEUMATIC AF TREATMENT USING VITAMIN K ANTAGONISTS, RIVAROXABAN OR ASPRIN STUDIES |
Principal Investigator(s) 1. Elijah Nyainda Ogola 2. felix ayub barasa Site(s) in Kenya 1. Kenyatta National hospital (Nairobi City county) 2. Moi teaching and Referral Hospital (Uasin Gishu county) 3. The Karen Hospital (Nairobi City county) |
View |
137. |
ECCT/16/10/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Professor Walter Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Research (Nairobi City county) 2. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) |
View |
138. |
ECCT/16/11/02 | IMPAACT P1093 Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents |
Principal Investigator(s) 1. Lucy Koech Site(s) in Kenya KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME |
View |
139. |
ECCT/16/11/03 | COAST Childrens Oxygen Administration Strategies Trial |
Principal Investigator(s) 1. Kathryn Maitland Site(s) in Kenya 1. Kilifi County Hospital (Kilifi county) 2. Coast Provincial General Hospital (Mombasa county) |
View |
140. |
ECCT/16/11/04 | RV456 A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo |
Principal Investigator(s) 1. JANET OYIEKO Site(s) in Kenya KOMBEWA CLINICAL RESEARCH CENTRE |
View |